StockData
Burning Rock Biotech Ltd logo

Burning Rock Biotech Ltd (BNR) stock

BNRNasdaqServices-Medical Laboratories
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 28, 2026Score 4/30
$12.50−0.24 (-1.88%)

Close on Nov 17, 2026Market cap $136.07MP/E –Yield –

Burning Rock Biotech r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was CN¥166.49M, down 28.3% from the year before. The highest annual figure on record is CN¥421.87M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025CN¥166.49M-28.3%
FY2024Dec 31, 2024CN¥232.29M-33.1%
FY2023Dec 31, 2023CN¥347.02M-17.7%
FY2022Dec 31, 2022CN¥421.87M+14.7%
FY2021Dec 31, 2021CN¥367.86M+39.4%
FY2020Dec 31, 2020CN¥263.94M+68.2%
FY2019Dec 31, 2019CN¥156.94M+49.0%
FY2018Dec 31, 2018CN¥105.30M–

More Burning Rock Biotech figures

See a number that looks wrong?